Cardima Showcases Next Generation Ablation System at the CardioRhythm 2007 Conference in Hong Kong
FREMONT, CA--(MARKET WIRE)--Feb 7, 2007 -- Cardima, Inc. (OTC BB:CADM.OB - News), developer of the REVELATION® Tx, REVELATION® T-Flex and REVELATION® Helix ablation microcatheters and INTELLITEMP® Energy Management Device, hosted a luncheon symposium at the CardioRhythm 2007 Conference which was held at the Hong Kong Convention and Exhibition Center on February 4th, 2007.
Cardima's luncheon symposium, entitled "New System and Techniques for Catheter-Based Treatment of Atrial Fibrillation," was held before an audience which included electrophysiology physicians from the Asia-Pacific nations, the European Union and North America.
Jaswinder Gill, MBBChir, MD, FRCP, Director of Pacing and Electrophysiology at Guy's and St. Thomas' Hospitals of the National Health Service, London, UK, described the first use of Cardima's next generation ablation system in the left atrium of a human heart. Cardima's ablation system is comprised of the INTELLITEMP® Energy Management Device and the REVELATION® T-Flex linear ablation catheter.
Dr. Gill is currently conducting a thirty patients trial using the Cardima ablation system. In the past two months, he has successfully isolated the pulmonary veins in eight patients suffering from atrial fibrillation. According to Dr. Gill, the system demonstrated a safety profile that confirmed prior animal studies conducted at the Stanford University School of Medicine by Sung Chun, MD, Director of Cardiac Pacing and Electrophysiology at Palo Alto Medical Foundation, California. Dr. Gill also indicated that he performed the catheter-based left atrial MAZE procedure in a shorter time and safer manner as compared to conventional radio frequency ablation methods.
"Cardima's multi-electrode linear ablation catheter requires less energy to create the lesions and it is faster than conventional devices, as the INTELLITEMP® device energizes multiple electrodes at the same time," said Dr. Gill.
Gabriel B. Vegh, Chief Executive Officer of Cardima, added, "I am pleased that the REVELATION® T-Flex and the INTELLITEMP® is as effective as was intended in the hands of Dr. Gill. His presentation in Hong Kong is an important step in introducing Cardima to the Chinese market."
About Cardima
Cardima, Inc. has developed the PATHFINDER® and REVELATION® Series of diagnostic catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). All of these devices are CE marked and received U.S. FDA 510(k) clearance. The REVELATION® Series of ablation catheters with the INTELLITEMP® EP Energy Management Device was developed and marketed for the treatment of atrial fibrillation (AF) after receiving CE mark approval in Europe; it is not currently available in the U.S.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the third quarter ended September 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.